Trial Summary
What is the purpose of this trial?This trial studies how well magnetic resonance whole body diffusion-weighted imaging works in finding cancer that has spread to the bone or lymph nodes (metastasis) in participants with high-risk prostate cancer. Diagnostic procedures, such as magnetic resonance whole body diffusion-weighted imaging (a method to show how water moves in a certain area) may help find bone or lymph nodes metastasis.
Eligibility Criteria
This trial is for individuals with high-risk prostate cancer, specifically those who have a PSA level over 20 ng/ml and/or a Gleason score of 8 or higher. Participants must be able to understand and sign consent. It's not for those on testosterone suppressing drugs, previous radiation therapy, low-risk patients (Gleason score < 8), or anyone who can't undergo MRI.Inclusion Criteria
My PSA level is over 20 ng/ml or my Gleason score is 8 or higher, indicating high-risk prostate cancer.
Ability to understand and sign informed consent
Exclusion Criteria
I have been treated with hormone therapy or radiation for my condition.
My initial Gleason score for prostate cancer was below 8, indicating low risk of spreading.
Contraindication to magnetic resonance imaging (MRI)
Participant Groups
The study is testing the effectiveness of magnetic resonance whole body diffusion-weighted imaging in detecting the spread of prostate cancer to bones or lymph nodes compared to traditional bone scans and CT scans.
1Treatment groups
Experimental Treatment
Group I: Diagnostic (bone scan, CT, MRI, magnetic resonance WB-DWI)Experimental Treatment4 Interventions
Participants undergo standard of care bone scan, CT of the abdomen and pelvis, and pelvic MRI. Participants also undergo magnetic resonance WB-DWI over 20-30 minutes.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
M D Anderson Cancer CenterHouston, TX
Loading ...
Who Is Running the Clinical Trial?
M.D. Anderson Cancer CenterLead Sponsor
National Cancer Institute (NCI)Collaborator